Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Status:
Not yet recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone,
in type-2 diabetic obese participants with Heart failure. The main question it aims to answer
are:
1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation
plays a key pathophysiologic role in the development of heart failure with preserved
ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals.
2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by
improving myocardial insulin sensitivity and by reducing both myocardial and epicardial
fat content.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio